CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Fostamatinib Disodium / R935788drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00706342
NCT00706342Phase 2Completed
CompareCT.gov

A Phase II, Open-Label, Efficacy and Safety, Ascending Dose, Pilot Study of be Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura

Rigel Pharmaceuticals·interventional·Posted Jun 27, 2008·Updated Jun 3, 2016

In Brief

A Phase 2 clinical trial evaluating Fostamatinib Disodium / R935788 for Purpura, Thrombocytopenic, Idiopathic. Completed, enrolled 18 participants across 2 sites.

Detailed Summary

The purpose of this study is to determine whether Fostamatinib Disodium is safe and effective in the treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPurpura, Thrombocytopenic, Idiopathic
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 27, 2008
Enrollment StartJan 1, 2007
Primary CompletionApr 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 18.0 years ago

Interventions

Fostamatinib Disodium / R935788drug

R935788 tablets